On Thursday, Stryker hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an upgrade to 82, up from 78 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.
Stryker is working on a consolidation with a 406.19 entry. See if it can clear the breakout price in volume at least 40% above average.
Earnings-per-share growth fell in the company's most recent report from 16% to 14%, but revenue rose from 11% to 12%.
The company holds the No. 8 rank among its peers in the Medical-Products industry group. Boston Scientific, Penumbra and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
